Onco Wiki / Biomarcador

HER2-baja (pecho IHC 1+ O IHC 2+ ISH-negativo)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDBIO-HER2-LOW
TipoBiomarcador
Aliaces
ERBB2 bajoHER2 IHC 1+HER2 IHC 2+/ISH-HER2-low (РМЗ — ІГХ 1+ АБО ІГХ 2+ ISH-)HER2-pecho bajo
Situaciónreviewed 2026-04-29 | pending_clinical_signoff
EnfermedadesDIS-BREAST
FuentesSRC-DESTINY-BREAST04-MODI-2022 SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025

Datos sobre biomarcadores

Tipo de biomarcadorprotein_expression_ihc
Medición
MétodoIHC (4B5 / HercepTest); reflejo ISH (FISH/CISH/SISH) para IHC 2+. La puntuación de mamas utiliza los criterios ASCO/CAP 2018 — tinción membranosa circunferencial ≥10%.
UnidadesIHC 0 | 1+ | 2+ (ISH-non-amplified) — HER2-low = IHC 1+ OR (IHC 2+ AND ISH HER2/CEP17 ratio <2.0 AND HER2 signals/cell <4.0)
Productos químicos y químicosBIO-HER2-SOLID BIO-ESTROGEN-RECEPTOR

Notas

HER2-low (IHC 1+ OR IHC 2+/ISH-) covers ~50-55% of HER2-non-positive breast cancers. DESTINY-Breast04 (Modi 2022) established T-DXd efficacy 2L+ in HER2-low metastatic breast (HR+ post-endocrine + ≥1 prior chemo, OR TNBC post-≥1 prior chemo): mPFS 9.9 vs 5.1 mo, OS 23.4 vs 16.8 mo. DESTINY-Breast06 extended signal to HER2-ultralow (IHC ≥0 with membrane staining) post-endocrine in HR+. Pathology challenge: IHC 1+ vs 0 has poor inter-observer reproducibility — ASCO/CAP 2023 update ongoing. ILD class warning (~12% any-grade, 1-2% G≥3) is dominant safety concern. Distinct from BIO-HER2-SOLID (which is named/scoped for gastric/GEJ/CRC scoring conventions).

Utilizado por

Relevancia terapéutica

Biomarcador

Capítulos del Manual

Preguntas del manual

Indicación